Robert Taub, President and Chief Executive Officer of OMRIX Biopharmaceuticals, Inc.,
Rings The NASDAQ Stock Market Opening Bell

Monday, June 5, 2006
at NASDAQ's MarketSite
in New York City.

OMRIX Biopharmaceuticals, Inc. [OMRI]

Robert Taub, President and Chief Executive Officer of OMRIX Biopharmaceuticals, Inc. (Nasdaq: OMRI) presides over the opening bell to celebrate its initial public offering on the NASDAQ.

OMRIX, a commercial-stage Company, develops and markets innovative biosurgical and passive immunotherapy products, utilizing its proprietary protein purification technology and manufacturing know-how. OMRIX commercializes its range of biosurgical hemostats through a partnership with Ethicon, Inc., a Johnson and Johnson company. Also through this partnership, OMRIX is developing highly-innovative surgical products that combine biologics with a surgical device to address unmet medical needs. OMRIX's business strategy includes proprietary product development for both its biosurgical and immunotherapy product lines and, where appropriate, partnering with companies whose development and/or commercial capabilities complement OMRIX's own areas of expertise. For more information, please visit: http://www.omrix.com.

Click for larger pictures of the NASDAQ MarketSite. Additional Photographs for 6/5/2006 Download Hi-Res Quality Photo of this NASDAQ Market Open - Pictured: Robert Taub, President and Chief Executive Officer of OMRIX Biopharmaceuticals, Inc., rings the Opening Bell These photos are Copyright 2006, The Nasdaq Stock Market Inc. and available for re-publication by the news media only. Any commercial use is strictly prohibited without the prior written consent of The Nasdaq Stock Market Inc. © Copyright 2006, The NASDAQ Stock Market, Inc. Reprinted with the permission of The Nasdaq Stock Market, Inc.